{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 1 Study of an oral, first-in-class, selective, and potent MMSET catalytic inhibitor that suppresses H3K36me2 in patients with Relapsed and Refractory Multiple Myeloma","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-1-study-of-an-oral-first-in-class-selective-and-potent-mmset-catalytic-inhibitor-that-suppresses-h3k36me2-in-patients-with-relapsed-and-refractory-multiple-myeloma\/#breadcrumbitem"}]}